Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Fresenius Kabi Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (285)
Cancellation by sponsor (141)
Prescription medicine registration (13)
Australian public assessment report (AusPar) (6)
Prescription medicine decision summary (2)

Date

2026 (10)
2025 (21)
2024 (49)
2023 (45)
2022 (28)
2021 (13)
2020 (29)
2019 (56)
2018 (15)
2017 (14)
2016 (18)
2015 (19)
2014 (7)
2013 (25)
2012 (18)
2011 (5)
2010 (5)
2009 (1)
2008 (13)
2007 (12)
2006 (26)
2002 (2)
2001 (2)
1994 (5)
1992 (3)
1991 (6)

Search

Sponsor content

447 result(s) found, displaying 211 to 220

IDACIO (Fresenius Kabi Australia Pty Ltd)

15 June 2020

Prescription medicine registration

Active ingredients: adalimumab.
PHOSPHOPREP Lemon Flavour Powder for solution sachet Cancelled under Section 41GL(d) of the Act

12 June 2020

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
GO KIT Cancelled under Section 41GL(d) of the Act

12 June 2020

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
GO KIT PLUS Cancelled under Section 41GL(d) of the Act

12 June 2020

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
PHOSPHOPREP Rasberry Flavour Powder for solution sachet Cancelled under Section 41GL(d) of the Act

12 June 2020

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
INTRALIPID 30% 250mL injection bottle Cancelled under Section 30(1)(c) of the Act

12 June 2020

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
INTRALIPID 30% 333mL injection bottle Cancelled under Section 30(1)(c) of the Act

12 June 2020

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
INTRALIPID 30% 500mL injection bottle Cancelled under Section 30(1)(c) of the Act

12 June 2020

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
INTRALIPID 30% 1L injection bottle Cancelled under Section 30(1)(c) of the Act

12 June 2020

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
Fresenius Kabi Australia Pty Ltd - Basic intravenous administration set (295276)

19 October 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Fresenius Kabi Australia Pty Ltd - Basic intravenous administration set.

Pages

First page
Previous page
…
Page 18
Page 19
Page 20
Page 21
Current page 22
Page 23
Page 24
Page 25
Page 26
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.